Cheng-Sánchez Iván, Gosselé Katherine A, Palaferri Leonardo, Kirillova Mariia S, Nevado Cristina
Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
ACS Med Chem Lett. 2024 Jan 26;15(3):355-361. doi: 10.1021/acsmedchemlett.3c00490. eCollection 2024 Mar 14.
Proteolysis Targeting Chimeras (PROTACs) are bifunctional molecules that simultaneously bind an E3 ligase and a protein of interest, inducing degradation of the latter via the ubiquitin-proteasome system. Here we present the development of degraders targeting CREB-binding protein (CBP) and E1A-associated protein (EP300)-two homologous multidomain enzymes crucial for enhancer-mediated transcription. Our PROTAC campaign focused on CPI-1612, a reported inhibitor of the histone acetyltransferase (HAT) domain of these two proteins. A novel asymmetric synthesis of this ligand was devised, while PROTAC-SAR was explored by measuring degradation, target engagement, and ternary complex formation . Our study demonstrates that engagement of Cereblon (CRBN) and a sufficiently long linker between the E3 and CBP/EP300 binders (≥21 atoms) are required for PROTAC-mediated degradation using CPI-1612 resulting in a new active PROTAC . Lessons learned from this campaign, particularly the importance of cell-based assays to understand the reasons underlying PROTAC performance, are likely applicable to other targets to assist the development of degraders.
蛋白酶靶向嵌合体(PROTACs)是双功能分子,可同时结合一种E3连接酶和一种目标蛋白,通过泛素-蛋白酶体系统诱导后者降解。在此,我们展示了针对CREB结合蛋白(CBP)和E1A相关蛋白(EP300)的降解剂的开发,这两种同源多结构域酶对增强子介导的转录至关重要。我们的PROTAC研究聚焦于CPI-1612,一种已报道的这两种蛋白的组蛋白乙酰转移酶(HAT)结构域抑制剂。设计了这种配体的新型不对称合成方法,同时通过测量降解、靶点结合和三元复合物形成来探索PROTAC的构效关系(SAR)。我们的研究表明,使用CPI-1612进行PROTAC介导的降解需要结合大脑神经酰胺酶(CRBN)以及E3与CBP/EP300结合剂之间有足够长的连接子(≥21个原子),从而产生一种新的活性PROTAC。从这项研究中吸取的经验教训,特别是基于细胞的分析对于理解PROTAC性能背后原因的重要性,可能适用于其他靶点,以协助降解剂的开发。